U.S. markets closed
  • S&P 500

    -27.29 (-0.72%)
  • Dow 30

    -177.26 (-0.57%)
  • Nasdaq

    -114.14 (-0.87%)
  • Russell 2000

    -32.15 (-1.49%)
  • Crude Oil

    -1.53 (-2.86%)
  • Gold

    -23.70 (-1.28%)
  • Silver

    -0.97 (-3.77%)

    -0.0071 (-0.58%)
  • 10-Yr Bond

    -0.0320 (-2.83%)

    -0.0108 (-0.79%)

    -0.0160 (-0.02%)

    +145.09 (+0.41%)
  • CMC Crypto 200

    -33.21 (-4.52%)
  • FTSE 100

    -66.25 (-0.97%)
  • Nikkei 225

    -179.08 (-0.62%)

SeeThruEquity Issues Update on Zomedica Pharmaceuticals Corp.

NEW YORK, NY / ACCESSWIRE / October 16, 2018 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (ZOM).

The report is available here: ZOM Update Note.

Based in Ann Arbor, MI, Zomedica Pharmaceuticals Corp. (NYSE American: ZOM, TSXV: ZOM, "Zomedica") is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine). Zomedica has a strong management team comprised of veterinarians, scientists, and experienced sales and marketing professionals. The company is led by Chairman and CEO Gerald Solensky Jr., who is supported by an impressive team of executives with senior-level experience at a number of leading companies in the animal healthcare space, including IDEXX Laboratories, among others. Zomedica's mission is to provide needs-driven solutions that give veterinarians the opportunity to lower costs, increase productivity and grow revenue while better serving the animals in their care. To achieve this mission, Zomedica established an extensive veterinarian engagement platform, Voice of The Vet™, and is developing a pipeline of diagnostics, instruments, therapeutics and drug delivery methods specifically designed to address unmet needs in healthcare for companion animals.

Highlights from the note include:

Zomedica continues to advance and expand its pipeline of diagnostic and therapeutic candidates for the companion animal market. The company recently reported significant new events as it prepares for the commercialization of its first diagnostics, including key hires and strategic partnerships that expand its portfolio. The company is expected to begin marketing activities in 2H18, with initial sales in 2019. Recent highlights are as follows:

  • Zomedica announces follow-on diagnostic ZM-020 following agreement with Seraph Biosciences. Zomedica recently added a high potential new product to its diagnostic portfolio as it gained an exclusive license to technology from Seraph Biosciences to introduce a new point of care instrument for pathogen detection, ZM-020. ZM-020 offers substantial benefits to existing methods for pathogen detection, such as faster, more accurate processing time; it will initially be marketed towards point of care fecal and urinary tract infection (UTI) testing. Zomedica expects to initiate marketing for ZM-020 in 4Q18.

  • Zomedica secures $3.5mn in new financing. Zomedica continues to make progress on the corporate front, as the company reported that it completed an aggregate of $4.0mn equity financing on June 28, 2018, offering 1.9mn shares at $2.15. Zomedica ended 2Q18 with cash on hand of approximately $4.3mn, which management will deploy to advance its therapeutic and diagnostic portfolio as well as to increase sales and marketing resources in preparation for commercial launch, which is expected in 2019.

  • Zomedica added to Russell 3000™ and Russel Microcap Indexes. Zomedica became included in the Russell 3000™ and Russell Microcap Indexes on June 25, 2018. The inclusion in the index is likely to increase awareness of Zomedica and has the potential to increase the company's prestige with potential new business and investor relationships.

Updating target to USD $3.54 / CAD $4.60 for Zomedica
We are updating our price target to USD $3.54 / CAD $4.60 for Zomedica following updates from the company that expand its diagnostics portfolio, as well as recent capital raising that reduces financial risk in the short run. We see Zomedica as pursuing a differentiated approach targeting unmet needs in diagnostics and therapeutics in the $10Bn companion animal market.

Please review important disclosures in the report and at www.seethruequity.com.

About Zomedica Pharmaceuticals Corp.
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) (ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica's mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. www.ZOMEDICA.com

About SeeThruEquity
Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative approach to deliver equity research of microcap and smallcap companies. SeeThruEquity has also been the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion since 2012.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.



SOURCE: SeeThruEquity